Beckman Coulter Ships New Highly Scalable Genetic Analysis System
FULLERTON, Calif. (January 7, 2004) – Beckman Coulter, Inc. (NYSE:BEC) began shipping its new GenomeLab SNPstream® Genotyping System. Capable of performing 4,600 to over 800,000 genotypes per day, SNPstream offers scalability unmatched by any genetic analysis system currently on the market.
“As researchers uncover new relevant SNPs (single nucleotide polymorphisms) and discover the utility of SNP genotyping for their particular study areas, their need for high throughput capability will expand,” said Elias Caro, president of Beckman Coulter’s Biomedical Research Division. “The scalability of this new product provides our customers the ability to easily transition from medium- to ultra high-throughput on a single instrument.”
SNPstream was developed as a result of Beckman Coulter’s acquisition of Orchid BioSciences’ SNP genotyping instruments, bioinformatic software and related consumables business. The new instrument is part of Beckman Coulter’s GenomeLab family of genetic analysis tools that innovate, simplify and automate genomics processes. Developed to enable the identification of new markers of biological, diagnostic and therapeutic interest, GenomeLab solutions help researchers identify the differences between normal and diseased states, isolate and purify samples, prepare nucleic acids, and analyze and evaluate genetic material. GenomeLab tools will be used in the validation of biomarkers and their association with specific disease states as well as in the evaluation of drug efficacy.
Beckman Coulter, Inc. is a leading manufacturer of instrument systems, chemistries and supplies that simplify and automate laboratory processes. At the forefront of medical discovery, in clinical research and through the often life-saving process of clinical diagnostics, Beckman Coulter’s 200,000 installed systems provide essential biomedical intelligence to enhance health care around the world. The company, based in Fullerton, Calif., reported 2002 annual sales of $2.06 billion with 62 percent of this amount generated by recurring revenue from supplies, test kits and services. For more information, see the company’s web site at www.beckmancoulter.com.
